These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16013931)

  • 1. [Correlation analysis between antipsychotic prescription quality and clinical status of patients with schizophrenia].
    Martínez Granados F; Moñino Martínez C; Pol Yanguas E; Ivorra Cano JM; Villar Malpica JL
    Farm Hosp; 2005 Mar; 29(2):95-103. PubMed ID: 16013931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.
    Rosa MA; Marcolin MA; Elkis H
    Braz J Psychiatry; 2005 Sep; 27(3):178-84. PubMed ID: 16224604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
    Alvarez E; Bobes J; Gómez JC; Sacristán JA; Cañas F; Carrasco JL; Gascón J; Gibert J; Gutiérrez M;
    Eur Neuropsychopharmacol; 2003 Jan; 13(1):39-48. PubMed ID: 12480121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose.
    Owen RR; Thrush CR; Kirchner JE; Fischer EP; Booth BM
    Int J Qual Health Care; 2000 Dec; 12(6):475-82. PubMed ID: 11202601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
    Mauri MC; Moliterno D; Rossattini M; Colasanti A
    Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia.
    Kaneda Y
    Clin Neuropharmacol; 2003; 26(4):182-4. PubMed ID: 12897637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological treatment resistant schizophrenia].
    Cervera Enguix S; Seva Fernández A
    Actas Esp Psiquiatr; 2006; 34(1):48-54. PubMed ID: 16525905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
    Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
    Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.
    Borison RL; Arvanitis LA; Miller BG
    J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of antipsychotic response in schizophrenia.
    Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM
    Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication.
    Rettenbacher MA; Hofer A; Eder U; Hummer M; Kemmler G; Weiss EM; Fleischhacker WW
    J Clin Psychiatry; 2004 Sep; 65(9):1211-8. PubMed ID: 15367047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The brief psychiatric rating scale: effect of scaling system on clinical response assessment.
    Thompson PA; Buckley PF; Meltzer HY
    J Clin Psychopharmacol; 1994 Oct; 14(5):344-6. PubMed ID: 7806691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.